Oligometastatic Disease: Practical Aspects of Metastasis-Directed Therapy in a Community Practice (PRO 08)
Recent studies have highlighted the role for radiation therapy among patients with oligometastatic disease in various states. This session aims to review recent clinical updates and practical aspects of implementation in a community-based setting, where comfort for adoption of this role for radiation therapy may be limited. Goals of the session also include reviewing dose, timing, patient selection, and technique considerations specific to a potentially resource-restricted setting.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, radiation dosimetrists, and radiation oncology residents.
Upon completion of this activity, participants should be able to do the following:
- Comfortably differentiate patients with oligometastatic disease that may benefit from radiation therapy in the context of recent supportive studies.
- Assess their available resources and apply safe, effective radiation when indicated with greater comfort of dose, technique, timing, and prognostication principles specific to metastasis-directed radiation
Beant Singh Gill, MD, is employed by Associates in Radiation Medicine and by Luminis Health. Dr. Gill holds an uncompensated faculty role with George Washington University. He is a Partner with Associates of Radiation Medicine. He serves as Medical Director for Chesapeake Potomac Regional Cancer Center and is a CAC Representative with the American College of Radiology.
David A. Palma, MD, PhD, is employed by Western University. He is an Independent Contractor with London Health Sciences Centre. He receives honoraria from UptoDate.com and Need, Inc. He owns stock in Need, Inc.
Melissa O’Neil, MRT(T), is employed by London Health Sciences Centre.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.